The impact and effectiveness of new coronavirus vaccine on disease outcome worldwide
19 Oct 2021-Vol. 3, Iss: 4, pp 332-340
About: The article was published on 2021-10-19 and is currently open access. It has received None citations till now. The article focuses on the topics: Coronavirus.
References
More filters
Chaolin Huang1, Yeming Wang2, Xingwang Li3, Lili Ren4, Jianping Zhao5, Yi Hu5, Li Zhang1, Guohui Fan2, Jiuyang Xu6, Xiaoying Gu2, Zhenshun Cheng7, Ting Yu1, Jia'an Xia1, Yuan Wei1, Wenjuan Wu1, Xuelei Xie1, Wen Yin5, Li Hui2, Min Liu2, Yan Xiao4, Hong Gao4, Li Guo4, Jungang Xie5, Guang-Fa Wang8, Rongmeng Jiang3, Zhancheng Gao8, Qi Jin4, Jianwei Wang4, Bin Cao2 •
TL;DR: The epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of patients with laboratory-confirmed 2019-nCoV infection in Wuhan, China, were reported.
36,578 citations
Nanshan Chen1, Min Zhou2, Xuan Dong1, Jie-Ming Qu2, Fengyun Gong1, Yang Han1, Yang Qiu3, Jingli Wang1, Ying Liu1, Yuan Wei1, Jia'an Xia1, Ting Yu1, Xinxin Zhang2, Li Zhang1 •
TL;DR: Characteristics of patients who died were in line with the MuLBSTA score, an early warning model for predicting mortality in viral pneumonia, and further investigation is needed to explore the applicability of the Mu LBSTA scores in predicting the risk of mortality in 2019-nCoV infection.
16,282 citations
Qiang Gao1, Linlin Bao2, Haiyan Mao3, Lin Wang1, Kangwei Xu, Minnan Yang4, Li Yajing1, Ling Zhu4, Nan Wang4, Zhe Lv4, Hong Gao2, Ge Xiaoqin1, Biao Kan5, Yaling Hu1, Jiangning Liu2, Fang Cai1, Deyu Jiang1, Yanhui Yin1, Cheng-Feng Qin6, Jing Li1, Xuejie Gong1, Xiuyu Lou3, Wen Shi3, Dongdong Wu1, Hengming Zhang1, Zhu Lang1, Wei Deng2, Li Yurong1, Jinxing Lu5, Changgui Li, Xiangxi Wang4, Weidong Yin1, Yanjun Zhang3, Chuan Qin2 •
TL;DR: Preclinical results of an early vaccine candidate called PiCoVacc, which protected rhesus macaque monkeys against SARS-CoV-2 infection when analyzed in short-term studies, support the clinical development and testing of Pi coVacc for use in humans.
Abstract: The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health crisis. There are currently no SARS-CoV-2-specific treatments or vaccines available due to the novelty of the virus. Hence, rapid development of effective vaccines against SARS-CoV-2 are urgently needed. Here we developed a pilot-scale production of a purified inactivated SARS-CoV-2 virus vaccine candidate (PiCoVacc), which induced SARS-CoV-2-specific neutralizing antibodies in mice, rats and non-human primates. These antibodies neutralized 10 representative SARS-CoV-2 strains, suggesting a possible broader neutralizing ability against SARS-CoV-2 strains. Three immunizations using two different doses (3 μg or 6 μg per dose) provided partial or complete protection in macaques against SARS-CoV-2 challenge, respectively, without observable antibody-dependent enhancement of infection. These data support clinical development of SARS-CoV-2 vaccines for humans.
1,161 citations
552 citations
Jeremy A W Gold1, Karen K. Wong1, Christine M Szablewski1, Priti R. Patel1, John Rossow1, Juliana Almeida da Silva1, Pavithra Natarajan1, Sapna Bamrah Morris1, Robyn Neblett Fanfair, Jessica Rogers-Brown1, Beau B. Bruce1, Sean D Browning1, Sean D Browning2, Alfonso C Hernandez-Romieu3, Nathan W. Furukawa1, Mohleen Kang3, Mary Evans1, Nadine Oosmanally, Melissa Tobin-D'Angelo, Cherie Drenzek, David J. Murphy3, Julie Hollberg3, James M. Blum3, Robert Jansen4, David W. Wright3, David W. Wright4, William Sewell5, Jack Owens5, Benjamin Lefkove3, Frank W. Brown3, Deron C. Burton1, Timothy M. Uyeki1, Stephanie R. Bialek1, Brendan R Jackson1 •
TL;DR: Medical record-abstracted data for hospitalized adult patients with laboratory-confirmed COVID-19 who were admitted during March 2020 revealed an overrepresentation of black patients within this hospitalized cohort, which is important for public health officials to ensure that prevention activities prioritize communities and racial/ethnic groups most affected by CO VID-19.
Abstract: SARS-CoV-2, the novel coronavirus that causes coronavirus disease 2019 (COVID-19), was first detected in the United States during January 2020 (1). Since then, >980,000 cases have been reported in the United States, including >55,000 associated deaths as of April 28, 2020 (2). Detailed data on demographic characteristics, underlying medical conditions, and clinical outcomes for persons hospitalized with COVID-19 are needed to inform prevention strategies and community-specific intervention messages. For this report, CDC, the Georgia Department of Public Health, and eight Georgia hospitals (seven in metropolitan Atlanta and one in southern Georgia) summarized medical record-abstracted data for hospitalized adult patients with laboratory-confirmed* COVID-19 who were admitted during March 2020. Among 305 hospitalized patients with COVID-19, 61.6% were aged <65 years, 50.5% were female, and 83.2% with known race/ethnicity were non-Hispanic black (black). Over a quarter of patients (26.2%) did not have conditions thought to put them at higher risk for severe disease, including being aged ≥65 years. The proportion of hospitalized patients who were black was higher than expected based on overall hospital admissions. In an adjusted time-to-event analysis, black patients were not more likely than were nonblack patients to receive invasive mechanical ventilation† (IMV) or to die during hospitalization (hazard ratio [HR] = 0.63; 95% confidence interval [CI] = 0.35-1.13). Given the overrepresentation of black patients within this hospitalized cohort, it is important for public health officials to ensure that prevention activities prioritize communities and racial/ethnic groups most affected by COVID-19. Clinicians and public officials should be aware that all adults, regardless of underlying conditions or age, are at risk for serious illness from COVID-19.
383 citations